Evaluating DPP4 inhibition and Bioequivalence of Vildagliptin 100mg SR ft Prof. Dr Aravinda Jagadeesha

Vildagliptin, a potent dipeptidyl peptidase IV inhibitor (DPP-4i), is usually administered twice daily to provide >90% inhibition of DPP-4 over 24 hours. Considering most type 2 diabetes (T2D) patients are on multiple medications, reducing dosing and pill burden can increase patient convenience.

In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr. Aravinds Diabetes Centre in Bengaluru, talks about how the DPP4 inhibition and bioequivalence of Vildagliptin 100mg SR would be.

Vildagliptin, a potent selective inhibitor of dipeptidyl peptidase-4 (DPP-4), works by increasing islet alpha-cell and beta-cell responsiveness to glucose which in turn improves glycaemic control.

Vildagliptin is known to be associated with a low risk of hypoglycaemia, and has an adverse event profile comparable to placebo, including a reduced rate of gastrointestinal adverse effects compared with metformin and a reduced rate of oedema

Vildagliptin 100mg Sustained release tablets have been studied to be bioequivalent to twice-daily Vildagliptin IR 50 mg. An open-label, the randomized study reported DPP-4 inhibition above 80% over 24 hours post-dose for the test product. Both once-daily Vildagliptin SR and twice-daily Vildagliptin IR demonstrated more than 80% DPP-4 inhibition till 24 h post-first dose. The DPP4 inhibition at 24 hrs was 89.58% with a single dose of once-daily Vildagliptin SR 100 mg tablet vs. 91.05% with twice-daily Vildagliptin IR 50 mg.

The evidence is based on a recently conducted Phase 4 clinical trial by researchers of Kolkata who confirmed the therapeutic equivalence of Vildagliptin 100 mg SR once daily with Vildagliptin 50mg twice daily. The data shows that the two therapies are equally effective in terms of reducing HbA1C, FBG, and PPBG. Both the drugs are equally safe in the parameter of changes in liver enzymes (SGOT and SGPT) and serum bilirubin.

Given the above findings, the overall profile of Vildagliptin 100mg sustained-release formulation suggests that DPP-4 inhibition could be an effective strategy to prevent or delay the progression of type 2 diabetes.